Year: 2026
Type: article
Study design: Case Report
Abstract: Objective: Anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) rearrangements are unique, mutually exclusive mutations that drive non-small cell lung cancer.Concurrent immunohistochemical positivity for both markers is exceedingly rare and may lead to diagnostic and therapeutic uncertainty, particularly when molecular confirmation is lacking. Case Presentation:A 54-year-old woman presented with a solitary brain metastasis and underwent surgical resection, followed by whole-brain radiotherapy with a focal boost.Histopathology confirmed metastatic lung adenocarcinoma.Baseline staging with positron emission tomographycomputed tomography (PET-CT) demonstrated a 20×19-mm hypermetabolic lingular lung nodule, mediastinal lymphadenopathy, and multiple sclerotic bone lesions.Immunohistochemistry of the tumor showed strong ALK (D5F3) and ROS1 (D4D6) expression, whereas deoxyribonucleic acidbased next-generation sequencing did not detect actionable rearrangements.Based on the immunophenotype, lorlatinib was initiated as first-line therapy.Serial PET-CT and brain magnetic resonance imaging demonstrated complete metabolic and radiologic remission of both intracranial and systemic disease, which has been sustained for nine months.Conclusion: This case illustrates a rare discordance between immunohistochemical and molecular findings.In this individual patient, treatment with lorlatinib coincided with sustained systemic and intracranial disease control.These observations should be interpreted cautiously, but may provide practical insights for similar complex clinical scenarios.
Source: Journal of Oncological Sciences
Authors: Neslihan ÖZYURT, Aykut TURHAN
Institution: Ordu University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7204756606
